INTRODUCTION
============

Breast cancer (BC) is the 2nd most common type of cancer in the world and the leading cancer type among women, with an estimated 1.67 million new cases diagnosed in 2012. Multiple factors, both genetic and nongenetic, are involved in its pathogenesis. Approximately 5% to 10% of all BC cases are considered to be hereditary.^[@R1]^ Previous studies showed that impaired DNA repair plays an important role in genetic instability and cancer development, especially during breast tumorigenesis.^[@R2]^

DNA molecule is constantly subjected to a wide variety of DNA damaging agents, either environmental (UV light, ionizing radiation, chemical poisons, and drugs) or endogenous (reactive oxygen species by products of routine metabolic processes) ones.^[@R3]^ DNA double-strand breaks (DSBs) are considered to be one of the most lethal forms of DNA damage, because a single unrepaired DSB results in a lethal cell growth arrest and an inhibition of cell cycle progression.^[@R4]^ An efficient DNA damage response signaling network commonly includes DNA repair pathways and tolerance mechanisms that, with cell cycle checkpoints, work together to ensure the integrity of the genome.^[@R5]^ DNA repair pathways include DNA strand break repair, mismatch repair, nucleotide excision repair, base excision repair, and ribonucleotide excision repair mechanisms.^[@R6]^ Loss of 1 DNA repair pathway constituent may be compensated for by an increase in the activity of different components of the same or other pathways. However, following major DSB lesions, these repair mechanisms are not effective in repairing DNA damage, because DNA molecule cannot serve as a template, and progression of the replication fork is impaired. Translesion DNA synthesis (TLS) can bypass damaged nucleosides and continue DNA replication, and this process is carried out by specialized DNA polymerases (β, ι, κ).^[@R7]^ Several recent studies reported possible association of DNA polymerase κ (*POLK*) with different types of cancer, for example, prostate cancer^[@R8]^ and nonsmall cell lung cancer.^[@R9]^ Until now, the link between *POLK* polymorphisms and BC has not been established.

Single nucleotide polymorphisms (SNPs) are thought to play an important role in genetic susceptibility to cancer. Numerous SNPs have been identified in the human *POLK* gene using sequence databases. We chose to investigate 3 *POLK* polymorphisms (rs3213801, rs10077427, and rs5744533) that are annotated in NCBI databases, but their association with BC risk was not previously determined. Herein, we conducted a case--control study to investigate this association in the Chinese Han population.

METHODS
=======

Study Subjects
--------------

BC case--control study was conducted in the Second Affiliated Hospital of Xi'an Jiaotong University, China, between January 2013 and October 2014. A total of 560 pathologically confirmed BC patients were enrolled without age restrictions and nonfamilial BC cases, while patients who had received chemotherapy or radiotherapy before surgery or had another type of cancer were excluded. Eligible controls (n = 583) were recruited from the same hospital who are taking part in routine examinations in the outpatient clinic and randomly matched to individuals in the patient group, based on race and age (±5 years). All subjects were unrelated Han Chinese individuals and residents of Northwest China. Study subjects who met the criteria and signed written informed consent were interviewed in order to obtain their medical histories and information about prescribed therapy and demographic factors, and to collect specimens.

Genotyping Assay
----------------

Blood samples from patients and healthy controls were collected in EDTA-containing tubes. DNA was extracted from peripheral blood samples following standard phenol--chloroform extraction procedure. The extracted DNA was quantitated spectrophotometrically and stored at −80 °C until further use. Three tag SNPs (rs3213801, rs10077427, and rs5744533) were selected for our study; according to the Chinese population data available through HapMap project (http://www.hapmap.org), these SNPs represented the majority of known common variants of *POLK*. Sequenom MassARRAY Assay Design 3.0 Software (Sequenom, Inc., San Diego, CA) was used to design a Multiplexed SNP MassEXTEND assay. SNP genotyping was performed with a Sequenom MassARRAY RS1000 (Sequenom, Inc.) following the standard protocol recommended by the manufacturer. The corresponding primers used for each SNP in our study are listed in Table [1](#T1){ref-type="table"}. Data analyses were performed using Sequenom Typer 3.0 Software (Sequenom, Inc.).
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Primers Used for This Study
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Statistical Analyses
--------------------

Statistical analyses were performed using the statistical software package SPSS 18. The polymorphisms were tested for Hardy--Weinberg Equilibrium. Differences between the patient and healthy control groups in the distributions of demographic characteristics, selected variables, and genotype frequencies of the 3 investigated SNPs were evaluated using the Student\'s *t*-test or χ^2^-test. Associations between POLK polymorphisms, BC risk, and the patients' clinical characteristics were assessed by computing odds ratios (ORs) and 95% confidence intervals (CIs) from unconditional logistic regression analysis, adjusting for age and body mass index. We evaluated the risk in the codominant model (Aa vs aa and AA vs aa; A represents the major allele, a the minor allele), dominant model (AA + Aa vs aa), recessive model (aa vs Aa + AA), overdominant model (aa + AA vs Aa), and the allele model (a vs A). A *P* value \<0.05 was considered statistically significant. All statistical tests were 2 sided.

RESULTS
=======

Patients and Healthy Controls Demographic Characteristics
---------------------------------------------------------

Baseline characteristics of the BC patient and control groups are described in Table [2](#T2){ref-type="table"}. The distributions of age, menopausal status, and procreative times were similar between BC patients and healthy controls. However, body mass index (BMI) values were lower than those of healthy subjects (*P* = 0.04). The proportions of patients with larger tumor size (≥2 cm), patients that were human epidermal growth factor receptor 2 negative, and patients with lower venous invasion were 66.4%, 69.5%, and 64.1%, respectively. The percentages of patients with positive lymph node metastasis, Scarff--Bloom--Richardson grade 1 to 2, positive estrogen receptor, positive progesterone receptor (PR), and higher Ki67 index (≥14%) were 57.9%, 55.2%, 55.9%, 54.5%, and 40.2%, respectively.
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Distributions of Select Variables in Breast Cancer Patients and Cancer-Free Controls
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Association Between *POLK* Polymorphisms and BC Risk
----------------------------------------------------

The genotype and allele frequencies of the *POLK* polymorphisms (rs3213801, rs10077427, and rs5744533) are shown in Table [3](#T3){ref-type="table"}. All polymorphisms conformed to Hardy--Weinberg Equilibrium (rs3213801: *P* = 0.86, rs10077427: *P* = 0.66, and rs5744533: *P* = 0.98).
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Genotype and Allele Frequencies of DNA Polymerase Kappa Polymorphisms Among the Cases and Controls and the Associations With Breast Cancer Risk

![](medi-95-e2466-g003)

Rs3213801 did not show any meaningful association with the increase or decrease in BC risk. The rs10077427 genotype frequency distribution in BC patients was: AA, 60.2%; GA, 35.5%; and GG 4.3%, while for in the controls these values are: AA, 66.4%; GA, 29.8%; and GG 3.8%. The GA genotype increased the risk of BC compared AA (GA vs AA: OR = 1.31, 95% CI = 1.02--1.69, *P* = 0.03). In a similar fashion, GA + GG genotype, and G allele were positively associated with BC risk. Rs5744533 showed a statistically significant association with an increased ORs under most models except recessive and overdominant model (CT vs CC: OR = 1.32, 95% CI = 1.03--1.69, *P* = `0`.03; TT vs CC: OR = 1.54, 95% CI = 1.02--2.32, *P* = 0.04; CT + TT vs CC: OR = 1.36, 95% CI = 1.08--1.72, *P* = 0.01; T vs C: OR = 1.27, 95% CI = 1.06--1.51, *P* = 0.009). These results suggested that POLK rs10077427 and rs5744533 polymorphisms may contribute to BC risk.

Genotype Associations With BC Risk by Menopausal Status
-------------------------------------------------------

Stratified analysis of the effects of rs10077427 and rs5744533 polymorphisms on BC risk by menopausal status is displayed in Table [4](#T4){ref-type="table"}. The results indicate that rs5744533 is associated with decreased BC susceptibility in postmenopausal women (OR = 0.64, 95% CI = 0.47--0.89, *P* = 0.008). However, there was no association between rs10077427 and BC risk in either premenopausal or postmenopausal patients.
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Genotype Association by Menopause Status Between DNA Polymerase Kappa Polymorphisms and Risk of Breast Cancer
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Relationship Between *POLK* Polymorphisms and Clinical Parameters of BC Patients
--------------------------------------------------------------------------------

*POLK* gene polymorphisms were also analyzed in order to establish their associations with clinicopathological features, including tumor size, lymph node metastasis, histological grade, venous invasion and the statuses of estrogen receptor, PR, human epidermal growth factor receptor 2, and Ki67. As shown in Table [5](#T5){ref-type="table"}, individuals with rs10077437 TC + CC genotype are more likely to have tumors that are PR-positive (OR = 1.54, 95% CI = 1.10--2.17, *P* = 0.01) and Ki67 ≥14% (OR = 1.58, 95% CI = 1.11--2.25, *P* = 0.01) compared with the TT genotype subjects. We found no relationship between any clinical parameters of BC patients and rs5744533.
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The Associations Between POLK Polymorphisms and Clinical Characteristics of Breast Cancer Patients
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DISCUSSION
==========

Genomic DNA replication is a prerequisite for cell proliferation. High fidelity of DNA replication is important for maintaining genetic information over many generations and avoiding the accumulation of deleterious mutations. On the other hand, low fidelity of DNA replication is necessary for the evolution of species, for generating diversity that can lead to increased survival and adaptability of species in the changing environment.^[@R10],[@R11]^ TLS, which largely depends on specialized DNA polymerases, repairs and replicates damage DNA with low fidelity.^[@R12]^ Y-family DNA polymerases are specialized polymerases involved in TLS, replicating damaged DNA, bypassing damaged nucleotides that block the normal progression of replication forks.^[@R13]^ Y-family is divided into 6 major groups based on amino acid sequence, which are represented by *Escherichia coli* Pol IV and Pol V, and 4 human enzymes, Pol η, ι, κ, and Rev1.^[@R14]^ These enzymes share a similar catalytic core in their N-terminal region and most of them have a noncatalytic C-terminus.^[@R15]^ The protein product of *POLK* gene is reported to be involved in checkpoint activation,^[@R16]^ rescue of methylnitrosourea-associated cytotoxicity,^[@R17]^ and microsatellite stability.^[@R18]^ POLK not only represents a DNA polymerase involved in the protection of cells from genotoxic DNA lesions, but is also included in genome integrity maintenance by acting as a noncatalytic protein against oxidative damage caused by hydrogen peroxide and menadione.^[@R19]^

Missense mutations of *POLK* (p.E29K, p.G154E, p.F155S, p.E430K, and p.L442F) were previously reported to be involved in prostate carcinogenesis, by diminishing the catalytic efficiencies of this polymerase.^[@R8]^ Overexpression of *POLK* was associated with advanced stages and poorer prognosis in glioma patients.^[@R20]^*POLK* gene plays an important role in DNA damage response and the upregulation of DNA damage response may cause cancer, as well as promote tumorigenesis.^[@R3]^ In our study, the role of *POLK* polymorphisms in BC was investigated for the first time, using a case--control approach. We observed that *POLK* genetic variants, rs10077427 and rs5744533, but not rs3213801, were positively associated with susceptibility to BC. Variants of these polymorphisms may affect the expression of *POLK* and eventually result in cancer. Overexpression of *POLK* results not only in increased spontaneous mutagenesis, but also in pleiotropic alterations such as DNA breaks, genetic exchanges, and aneuploidy.^[@R21]^ Furthermore, we showed that the rs5744533 polymorphism in *POLK* gene was inversely associated with positive PR status and Ki67 index. The rs10077427 genetic variant was more frequent in premenopausal women. Shao et al^[@R9]^ found that carriers with AA genotype of *POLK* rs5744533 and rs3213801 were more likely to respond to the platinum-based chemotherapy treatment and the patients carrying rs10077427 A allele had decreased progression-free survival (PFS). Our results indicate that these 2 polymorphisms in *POLK* gene may determine susceptibility to BC in individuals from the northwest of China.

The limitations of the present study were following:BC is a disease caused by multiple factors, but we have not investigated the effect of wide array of factors, including family heredity history, endocrine factors, environmental influences, and style of life.In this study, the 3 investigated polymorphisms were independently evaluated for susceptibility to BC, without considering the effect of and interactions with other variants.

In conclusion, our case--control study indicates that *POLK* polymorphisms have significant effects on the susceptibility and progression of BC among Han Chinese women. Further research on *POLK* polymorphisms is required to validate our findings. Because BC is a prevalent disease among the female population worldwide, identifying potential predictive and prognostic markers for this disease is of great significance for diagnosing and treating BC in general population.
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